Journal: Cell and Tissue Banking

Article Title: The promising approach of MSCs therapy for COVID-19 treatment

doi: 10.1007/s10561-022-10060-2

Figure Lengend Snippet: The MSCs therapy functional mechanism for COVID-19 treatment

Article Snippet: NCT04492501 , Role of investigational therapies alone or in combination to treat moderate, severe and critical COVID-19 , UNICEF/Pakistan , 600 , Procedure: Therapeutic plasma exchange Biological: Convalescent Plasma Drug: Tocilizumab Drug: Remdesivir Biological: MSC therapy , Not Applicable , In an attempt to treat COVID-19, investigator used different investigational treatment either alone or in combination to see mortality and morbidity benefit on the basis of limited evidence available so far. These investigational modalities included therapeutic plasma exchange, convalescent plasma, remdesivir, tocilizumab and MSC therapy in addition to standard supportive treatment..

Techniques: Functional Assay

Journal: Cell and Tissue Banking

Article Title: The promising approach of MSCs therapy for COVID-19 treatment

doi: 10.1007/s10561-022-10060-2

Figure Lengend Snippet: Summarized clinical trial (marked “completed”) studies on the MSCs in the COVID-19 ( https://www.clinicaltrials.gov )

Article Snippet: NCT04492501 , Role of investigational therapies alone or in combination to treat moderate, severe and critical COVID-19 , UNICEF/Pakistan , 600 , Procedure: Therapeutic plasma exchange Biological: Convalescent Plasma Drug: Tocilizumab Drug: Remdesivir Biological: MSC therapy , Not Applicable , In an attempt to treat COVID-19, investigator used different investigational treatment either alone or in combination to see mortality and morbidity benefit on the basis of limited evidence available so far. These investigational modalities included therapeutic plasma exchange, convalescent plasma, remdesivir, tocilizumab and MSC therapy in addition to standard supportive treatment..

Techniques: Injection, Marker, Real-time Polymerase Chain Reaction, Transplantation Assay, Infection, Modification, Ex Vivo, Derivative Assay, Flow Cytometry

Journal: Pharmacy and Therapeutics

Article Title: Ledipasvir/Sofosbuvir (Harvoni): Improving Options for Hepatitis C Virus Infection

doi:

Figure Lengend Snippet: Comparison of Class I, Level A Recommendations: Harvoni and Viekira Pak 18 – 20 , 26 – 28

Article Snippet: Brief Summary of HCV Treatment Guidelines in Patients Who Are HCV Genotype 1–Positive And Failed Prior PEG/RBV Therapy 25 table ft1 table-wrap mode="anchored" t5 Table 3 caption a7 Harvoni (LDV/SOF) Viekira Pak (OBV/PTV/r + DSV ± RBV) Trial Name ION I ION II ION III SAPPHIRE I PEARL III PEARL IV TURQUOISE II Study population Treatment-naïve GT 1 null-responders Treatment-naïve with no cirrhosis Treatment-naïve with no cirrhosis GT 1b treatment-naïve with no cirrhosis GT 1a treatment-naïve with no cirrhosis Compensated cirrhosis Treatment regimen LDV/SOF ± RBV LDV/SOF ± RBV LDV/SOF ± RBV OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV ± RBV OBV/PTV/r + DSV ± RBV OBV/PTV/r + DSV + RBV Number of patients enrolled 865 440 647 631 419 305 380 Treatment duration 12 or 24 weeks 12 or 24 weeks 8 or 12 weeks 12 weeks 12 weeks 12 weeks 12 or 24 weeks SVR12 97%–99% 94%–99% 93%–95% 96.2% 99.5%–99.0% 90.2%–97% 91.8%–95.9% Relapse 2 11 23 7 1 11 13 Breakthrough 0 1 0 1 0 7 4 Discontinuation due to adverse events 0 0 3 4 0 2 8 Open in a separate window DSV = dasabuvir; GT = genotype; LDV = ledipasvir; OBV = ombitasvir; PTV = paritaprevir; r = ritonavir; RBV = ribavirin; SOF = sofosbuvir; SVR12 = sustained virological response 12 weeks after treatment Comparison of Class I, Level A Recommendations: Harvoni and Viekira Pak 18 – 20 , 26 – 28

Techniques: